Autoimmune, Cholestatic, and Biliary Disease

You have full text access to this OnlineOpen article

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis†

  1. Keith D. Lindor1,‡,*,
  2. Kris V. Kowdley2,
  3. Velimir A. C. Luketic3,
  4. M. Edwyn Harrison4,
  5. Timothy McCashland5,
  6. Alex S. Befeler6,
  7. Denise Harnois7,
  8. Roberta Jorgensen1,
  9. Jan Petz1,
  10. Jill Keach1,
  11. Jody Mooney2,
  12. Carol Sargeant3,
  13. Julie Braaten4,
  14. Tamara Bernard5,
  15. Debra King6,
  16. Ellen Miceli7,
  17. Jeff Schmoll8,
  18. Tanya Hoskin8,
  19. Prabin Thapa8,
  20. Felicity Enders8

Article first published online: 20 MAY 2009

DOI: 10.1002/hep.23082

Issue

Hepatology

Hepatology

Volume 50, Issue 3, pages 808–814, September 2009

Additional Information

How to Cite

Lindor, K. D., Kowdley, K. V., Luketic, V. A. C., Harrison, M. E., McCashland, T., Befeler, A. S., Harnois, D., Jorgensen, R., Petz, J., Keach, J., Mooney, J., Sargeant, C., Braaten, J., Bernard, T., King, D., Miceli, E., Schmoll, J., Hoskin, T., Thapa, P. and Enders, F. (2009), High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology, 50: 808–814. doi: 10.1002/hep.23082

Author Information

  1. 1

    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN

  2. 2

    Center for Liver Disease, Virginia Mason Medical Center, Seattle, WA

  3. 3

    Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University School of Medicine, Richmond, VA

  4. 4

    Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, AZ

  5. 5

    Department of Internal Medicine, University of Nebraska, Lincoln, NE

  6. 6

    Division of Gastroenterology and Hepatology; Saint Louis University, St. Louis, MO

  7. 7

    Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL

  8. 8

    Biostatistics and Health Sciences Research; Mayo Clinic, Rochester, MN

  1. ‡

    fax: 507-266-4531.

*Mayo Clinic, Fiterman Center for Digestive Diseases, 200 First Street, SW, Rochester, MN 55905

  1. †

    Potential conflicts of interest: none.

Publication History

  1. Issue published online: 27 AUG 2009
  2. Article first published online: 20 MAY 2009
  3. Accepted manuscript online: 20 MAY 2009 12:00AM EST
  4. Manuscript Accepted: 11 MAY 2009
  5. Manuscript Received: 19 MAR 2009

Funded by

  • National Institute of Diabetes and Digestive and Kidney Diseases. Grant Number: 56924
  • Axcan Pharma
  • National Center for Research Resources (awarded to Virginia Commonwealth University). Grant Number: M01RR000065

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (319K)

References

  • 1
    Silveira MG, Lindor KD. Primary sclerosing cholangitis. Can J Gastroenterol 2008; 22: 689–698.
  • 2
    Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003; 125: 1364–1369.
  • 3
    Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994; 106: 494–499.
  • 4
    Angulo P, Batts KP, Jorgensen RA, LaRusso NA, Lindor KD. Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000; 95: 2333–2337.
    Direct Link:
  • 5
    Sandborn WJ, Wiesner RH, Tremaine WJ, Larusso NF. Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. Gut 1993; 34: 242–246.
  • 6
    Van Thiel DH, Wright H, Carroll P, Abu-Elmagd K, Rodriguez-Rilo H, McMichael J, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995; 90: 771–776.
  • 7
    Talwalkar JA, Gossard AA, Keach JC, Jorgensen RA, Petz JL, Lindor KD. Tacrolimus for the treatment of primary sclerosing cholangitis. Liver Int 2007; 27: 451–453.
    Direct Link:
  • 8
    Olsson R, Broome U, Danielsson A, Hagerstrand I, Jarnerot G, Loof L, et al. Colchicine treatment of primary sclerosing cholangitis. Gastroenterology 1995; 108: 1199–1203.
  • 9
    Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336: 691–695.
  • 10
    Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001; 121: 900–907.
  • 11
    Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005; 129: 1464–1472.
  • 12
    Harnois DM, Angulo P, Jorgensen RA, Larusso NF, Lindor KD. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001; 96: 1558–1562.
    Direct Link:
  • 13
    Kim WR, Therneau TM, Wiesner RH, Poterucha JJ, Benson JT, Malinchoc M, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000; 75: 688–694.
  • 14
    Angulo P, Dickson ER, Therneau TM, Jorgensen RA, Smith C, DeSotel CK, et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999; 30: 830–835.
  • 15
    Benedetti A, Alvaro D, Bassotti C, Gigliozzi A, Ferretti G, La Rosa T, et al. Cytotoxicity of bile salts against biliary epithelium: a study in isolated bile ductule fragments and isolated perfused rat liver. HEPATOLOGY 1997; 26: 9–21.
    Direct Link:
  • 16
    Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Weiglein AH, Lammert F, et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002; 123: 1238–1251.
  • 17
    Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998; 101: 2790–2799.
  • 18
    Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman RW. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 2008; 48: 792–800.
View Full Article (HTML) Get PDF (319K)